PT  - JOURNAL ARTICLE
AU  - Minnier, Jessica
AU  - Huffman, Jennifer E
AU  - Gao, Lina
AU  - Joseph, Jacob
AU  - Wan, Emily S
AU  - Wu, Wen-Chih
AU  - Suzuki, Ayako
AU  - Pathak, Gita A
AU  - Polimanti, Renato
AU  - Arjomandi, Mehrdad
AU  - Chang, Kyong-Mi
AU  - Garcon, Helene
AU  - Verma, Anurag
AU  - Ho, Yuk-Lam
AU  - Meigs, James B
AU  - Cho, Kelly
AU  - Bonomo, Robert A
AU  - Gorman, Bryan R
AU  - Pyarajan, Saiju
AU  - Gatsby, Elise
AU  - Rajeevan, Nallakkandi
AU  - Lynch, Kristine E
AU  - Lynch, Julie A
AU  - Zekavat, Seyedeh Maryam
AU  - Natarajan, Pradeep
AU  - Madison, Cecelia J
AU  - Zhou, Jin J
AU  - Jhala, Darshana N
AU  - Donskey, Curtis J
AU  - McGeary, John E
AU  - Reaven, Peter D
AU  - Sun, Yan V
AU  - Freiberg, Mat
AU  - Gelernter, Joel
AU  - Petersen, Jeffrey M
AU  - Hung, Adriana
AU  - Huang, Rose DL
AU  - Madduri, Ravi K
AU  - Dalal, Sharvari
AU  - Wells, Quinn S
AU  - Liao, Katherine P
AU  - Wilson, Peter W.F.
AU  - Tsao, Philip S
AU  - O’Donnell, Christopher J
AU  - Gaziano, John M
AU  - ,
AU  - Hauger, Richard L
AU  - Iyengar, Sudha K.
AU  - Luoh, Shiuh-Wen
TI  - Polygenic predisposition to venous thromboembolism is associated with increased COVID-19 positive testing rates
AID  - 10.1101/2022.01.29.22270094
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.29.22270094
4099  - http://medrxiv.org/content/early/2022/01/31/2022.01.29.22270094.short
4100  - http://medrxiv.org/content/early/2022/01/31/2022.01.29.22270094.full
AB  - Genetic predisposition to venous thrombosis may impact COVID-19 infection and its sequelae. Participants in the ongoing prospective cohort study, Million Veteran Program (MVP), who were tested for COVID-19, with European ancestry, were evaluated for associations with polygenic venous thromboembolic risk, Factor V Leiden mutation (FVL) (rs6025) and prothrombin gene 3’ -UTR mutation (F2 G20210A)(rs1799963), and their interactions. Logistic regression models assessed genetic associations with VTE diagnosis, COVID-19 (positive) testing rates and outcome severity (modified WHO criteria), and post-test conditions, adjusting for outpatient anticoagulation medication usage, age, sex, and genetic principal components. 108,437 out of 464,961 European American MVP participants were tested for COVID-19 with 9786 (9%) positive. PRS(VTE), FVL, F2 G20210A were not significantly associated with the propensity of being tested for COVID-19. PRS(VTE) was significantly associated with a positive COVID-19 test in F5 wild type (WT) individuals (OR 1.05; 95% CI [1.02-1.07]), but not in FVL carriers (0.97, [0.91-1.94]). There was no association with severe outcome for FVL, F2 G20210A or PRS(VTE). Outpatient anticoagulation usage in the two years prior to testing was associated with worse clinical outcomes. PRS(VTE) was associated with prevalent VTE diagnosis among both FVL carriers or F5 wild type individuals as well as incident VTE in the two years prior to testing. Increased genetic propensity for VTE in the MVP was associated with increased COVID-19 positive testing rates, suggesting a role of coagulation in the initial steps of COVID-19 infection.Key PointsIncreased genetic predisposition to venous thrombosis is associated with increased COVID-19 positive testing rates.PRS for VTE further risk stratifies factor V Leiden carriers regarding their VTE risk.Competing Interest StatementC.J.O. declares employment by Novartis Institute of Biomedical Interest. The remaining authors declare no competing financial interests.Funding StatementThis research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by award # MVP035. This publication does not represent the views of the Department of Veteran Affairs or the United States Government. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The MVP protocol was approved by the VA Central Institutional Review Board in accordance with principles outlined in the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFull GWAS summary statistics from published MVP investigations are available in dbGaP (https://www.ncbi.nlm.nih.gov/gap) under the MVP accession (phs001672). Individual-level genotype or clinical data cannot be shared outside of MVP.